<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293135</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00961-46</org_study_id>
    <nct_id>NCT02293135</nct_id>
  </id_info>
  <brief_title>Evaluation of Stendo Pulsating Suit on Microcirculation and Endothelial Function in Diabetic Patients</brief_title>
  <acronym>Diabete_1</acronym>
  <official_title>Evaluation of the Action of the Stendo Pulsating Suit on Peripheral Microcirculation and on Endothelial Function in Diabetic Patients Without Complication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stendo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stendo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The action of one Stendo pulsating suit session will be evaluated on 16 type 2 diabetic
      patients referred on the diabetic consultations. The effects of one Stendo pulsating suit
      session system will be assessed on the peripheral cutaneous microcirculation and on
      endothelial functions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of the endothelium in micro-vascular system is mediated by synthesis and release of
      numerous substances that act on the smooth muscle fibers. The release of these products is
      modulated, in turn, by various circulating molecules, by autonomic nervous system and by
      local mechanical factors such as shear stress.

      The type 2 diabetes leads to early vascular redesign with the onset of endothelial
      dysfunction and the worsening of the arterial stiffness.

      These anomalies, well correlated with the cardiovascular risks, are currently investigated in
      the department of Endocrinology, Diabetes, and Nutrition at the Jean Verdier Hospital. The
      analysis methods allow identifying early modifications in response to various drugs,
      nutritional or physical stimuli.

      The aim of this study is therefore to evidence a peripheral microcirculation and endothelial
      function improvement in type 2 diabetic patient in comparison to a cross-over control
      session.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral microcirculation measured using Laser Doppler flowmetry</measure>
    <time_frame>30 minutes after the end of the Stendo session</time_frame>
    <description>Change in % of the peripheral cutaneous microcirculation using laser Doppler flowmetry after one Stendo pulsating suit session</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>10 minutes after the end of Stendo session</time_frame>
    <description>Change of arterial stiffness using an applanation tonometry device after one Stendo pulsating suit session; Augmentation Index and sub-endocardial viability ratio will also be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (HRV)</measure>
    <time_frame>15 minutes after the end of Stendo session</time_frame>
    <description>HRV is calculated from continuous noninvasive arterial pressure records and continuous high resolution 3-lead, 6channel ECG records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelium-dependant microvascular flow after local acetylcholine iontophoresis</measure>
    <time_frame>35 minutes after the end of Stendo session</time_frame>
    <description>3 minutes Area Under Curve (AUC) of the peripheral microcirculation using Laser Doppler flowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>45 minutes after the end of Stendo session</time_frame>
    <description>RHI is the post-to-pre occlusion Peripheral Arterial Tone (PAT) signal ratio in the occluded arm, relative to the same ratio in the control arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verum Stendo session on V1 and Phantom Stendo session on V2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phantom Stendo session on V1 and Verum Stendo session on V2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verum Stendo session on V1 and Phantom Stendo session on V2</intervention_name>
    <description>On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phantom Stendo session on V1 and Verum Stendo session on V2</intervention_name>
    <description>On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic patient

          -  Diagnosis of diabetes &gt; 1 year

          -  HBA1c between 6 and 8,5

          -  Treated with oral anti-diabetic, insulin and/or incretins which can be stayed
             unchanged during the 2-week study

        Exclusion Criteria:

          -  Type 1 diabetic Patient

          -  Antecedent of cardiomyopathy, cardiac ischemia or valvulopathy

          -  Severe kidney failure

          -  Non controlled hypertension (&gt; 160/100mm Hg)

          -  Cardiac arrhythmia

          -  Severe respiratory failure

          -  Patient with an advanced obstructive arterial disease

          -  Patient with a recent and progressive deep venous thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul VALENSI, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Jean Verdier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul VALENSI, Professor</last_name>
    <phone>+33 1 48 02 65 97</phone>
    <email>paul.valensi@jvr.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Badreddine MERIOUD, MD</last_name>
    <phone>+ 33 148 02 65 99</phone>
    <email>badreddine.merioud@jvr.ap-hop-paris.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Jean Verdier, Service d'Endocrinologie Diabétologie Nutrition</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes ; endothelium stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

